Product
Help
Pricing
About
Jobs
Log in
Get started
Institution
Add to collection
Kansai Medical University Hospital
Homepage:
hp.kmu.ac.jp
Alternate name:
関西医科大学附属病院
Related institution:
Kansai Medical University
ROR:
04gpc9445
OpenAlex ID:
I4405284950
Works
1,483
Awards
3
Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer
2017
·
Jean-Charles Soria
, Yuichiro Ohe
, et al.
·
New England Journal of Medicine
·
5,649
PDF
Overall Survival with Osimertinib in Untreated, EGFR -Mutated Advanced NSCLC
2019
·
Suresh S. Ramalingam
, Johan Vansteenkiste
, et al.
·
New England Journal of Medicine
·
3,012
PDF
Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
2022
·
David R. Spigel
, Corinne Faivre-Finn
, et al.
·
Journal of Clinical Oncology
·
1,527
Assessing interactions in the brain with exact low-resolution electromagnetic tomography
2011
·
Roberto D. Pascual-Marqui
, Dietrich Lehmann
, et al.
·
Philosophical Transactions of the Royal Society A Mathematical Physical and Engineering Sciences
·
850
PDF
Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non–Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study
2023
·
Marina C. Garassino
, Shirish Gadgeel
, et al.
·
Journal of Clinical Oncology
·
778
PDF
Transversus Abdominis Plane Block: An Updated Review of Anatomy and Techniques
2017
·
Hsiao-Chien Tsai
, Takayuki Yoshida
, et al.
·
BioMed Research International
·
485
PDF
Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC—an Update From the PACIFIC Trial
2021
·
Corinne Faivre-Finn
, David Vicente
, et al.
·
Journal of Thoracic Oncology
·
471
Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC
2019
·
Jhanelle E. Gray
, Augusto Villegas
, et al.
·
Journal of Thoracic Oncology
·
430
Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189
2021
·
D. Rodríguez-Abreu
, S.F. Powell
, et al.
·
Annals of Oncology
·
424
PDF
Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial
2019
·
C. Morizane
, T. Okusaka
, et al.
·
Annals of Oncology
·
326
JCS/JACR 2021 Guideline on Rehabilitation in Patients With Cardiovascular Disease
2022
·
Shigeru Makita
, Takanori Yasu
, et al.
·
Circulation Journal
·
314
PDF
Efficacy and Safety of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy
2017
·
Adrian Koh
, Timothy Y. Y. Lai
, et al.
·
JAMA Ophthalmology
·
310
PDF
The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group
2021
·
Khalid El Bairi
, Harry R. Haynes
, et al.
·
npj Breast Cancer
·
286
PDF
Segmentectomy for ground-glass-dominant lung cancer with a tumour diameter of 3 cm or less including ground-glass opacity (JCOG1211): a multicentre, single-arm, confirmatory, phase 3 trial
2023
·
Keiju Aokage
, Kenji Suzuki
, et al.
·
The Lancet Respiratory Medicine
·
249
Validity and reliability of a performance evaluation tool based on the modified Barthel Index for stroke patients
2017
·
Tomoko Ohura
, Kimitaka Hase
, et al.
·
BMC Medical Research Methodology
·
240
The path to a better biomarker: application of a risk management framework for the implementation of PD‐L1 and TILs as immuno‐oncology biomarkers in breast cancer clinical trials and daily practice
2020
·
Paula I Gonzalez‐Ericsson
, Elisabeth S Stovgaard
, et al.
·
The Journal of Pathology
·
215
Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study
2019
·
Rina Hui
, Mustafa Özgüroğlu
, et al.
·
The Lancet Oncology
·
190
Outcomes With Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With NSCLC and Stable Brain Metastases: Pooled Analysis of KEYNOTE-021, -189, and -407
2021
·
Steven F. Powell
, Delvys Rodríguez-Abreu
, et al.
·
Journal of Thoracic Oncology
·
189
PDF
Randomized Phase II Trial Comparing Site-Specific Treatment Based on Gene Expression Profiling With Carboplatin and Paclitaxel for Patients With Cancer of Unknown Primary Site
2019
·
Hidetoshi Hayashi
, Takayasu Kurata
, et al.
·
Journal of Clinical Oncology
·
173
Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group
2020
·
Mohamed Amgad
, Elisabeth Specht Stovgaard
, et al.
·
npj Breast Cancer
·
172
PDF
Overall Survival with Amivantamab–Lazertinib in EGFR -Mutated Advanced NSCLC
2025
·
James Chih-Hsin Yang
, Shun Lu
, et al.
·
New England Journal of Medicine
·
165
Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset
2018
·
Yuichiro Ohe
, Fumio Imamura
, et al.
·
Japanese Journal of Clinical Oncology
·
158
PDF
Ultrasound-Guided Obturator Nerve Block: A Focused Review on Anatomy and Updated Techniques
2017
·
Takayuki Yoshida
, Tatsuo Nakamoto
, et al.
·
BioMed Research International
·
153
PDF
The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV
2019
·
Hiroaki Akamatsu
, Kiichiro Ninomiya
, et al.
·
International Journal of Clinical Oncology
·
149
PDF
Comprehensive Diagnostic Criteria for IgG4-Related Disease
2013
·
Hisanori Umehara
, Kazuichi Okazaki
·
Springer eBooks
·
149
Show more works
View as search
Works count:
1,483
Citation count:
171,600
Year
Topic
Type
